{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:19:11Z","timestamp":1781871551444,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T00:00:00Z","timestamp":1676678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009158","name":"Kawasaki Medical School","doi-asserted-by":"publisher","award":["R03B-019"],"award-info":[{"award-number":["R03B-019"]}],"id":[{"id":"10.13039\/501100009158","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.numecd.2023.02.011","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T22:12:52Z","timestamp":1677017572000},"page":"1444-1452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9734-9780","authenticated-orcid":false,"given":"Yukino","family":"Katakura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4223-9613","authenticated-orcid":false,"given":"Masashi","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mana","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Wamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Fushimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpei","family":"Sanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Obata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1392-0637","authenticated-orcid":false,"given":"Fuminori","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoatsu","family":"Mune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Kaneto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.numecd.2023.02.011_bib1","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1161\/ATVBAHA.111.226100","article-title":"Triglycerides and heart disease: still a hypothesis?","volume":"31","author":"Goldberg","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2023.02.011_bib2","article-title":"Small, dense low-density lipoprotein-cholesterol and atherosclerosis: relationship and therapeutic strategies","volume":"8","author":"Jin","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"19","key":"10.1016\/j.numecd.2023.02.011_bib3","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.numecd.2023.02.011_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00041433-199906000-00007","article-title":"Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis","volume":"10","author":"Fruchart","year":"1999","journal-title":"Curr Opin Lipidol"},{"issue":"20","key":"10.1016\/j.numecd.2023.02.011_bib5","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.numecd.2023.02.011_bib6","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.numecd.2023.02.011_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","year":"2000","journal-title":"Circulation"},{"issue":"9500","key":"10.1016\/j.numecd.2023.02.011_bib8","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet (London, England)"},{"issue":"17","key":"10.1016\/j.numecd.2023.02.011_bib9","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.numecd.2023.02.011_bib10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","article-title":"Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis","volume":"217","author":"Lee","year":"2011","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.numecd.2023.02.011_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/17425255.2018.1483337","article-title":"Peroxisome proliferator-activated receptor alpha-mediated drug toxicity in the liver","volume":"14","author":"Hedrington","year":"2018","journal-title":"Expet Opin Drug Metabol Toxicol"},{"issue":"20","key":"10.1016\/j.numecd.2023.02.011_bib12","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.jacc.2012.07.049","article-title":"Effects of fibrates in kidney disease: a systematic review and meta-analysis","volume":"60","author":"Jun","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.numecd.2023.02.011_bib13","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00228-009-0723-7","article-title":"Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report","volume":"65","author":"Wu","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"issue":"9729","key":"10.1016\/j.numecd.2023.02.011_bib14","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.numecd.2023.02.011_bib15","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/13543784.2017.1312339","article-title":"PPAR-alpha agonists are still on the rise: an update on clinical and experimental findings","volume":"26","author":"Ferri","year":"2017","journal-title":"Expet Opin Invest Drugs"},{"issue":"1","key":"10.1016\/j.numecd.2023.02.011_bib16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.numecd.2023.02.011_bib17","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.numecd.2023.02.011_bib18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep4.1019","article-title":"Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies","volume":"1","author":"Akuta","year":"2017","journal-title":"Hepatol Commun"},{"issue":"10019","key":"10.1016\/j.numecd.2023.02.011_bib19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.numecd.2023.02.011_bib20","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.numecd.2023.02.011_bib21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2023.02.011_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejphar.2015.12.043","article-title":"Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model","volume":"772","author":"Orime","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.numecd.2023.02.011_bib23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1475-2840-12-82","article-title":"Selective peroxisome proliferator-activated receptor \u03b1 modulators (SPPARM\u03b1): the next generation of peroxisome proliferator-activated receptor \u03b1-agonists","volume":"12","author":"Fruchart","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.numecd.2023.02.011_bib24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","article-title":"Effects of K-877, a novel selective PPARalpha modulator (SPPARMalpha), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial","volume":"249","author":"Ishibashi","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2023.02.011_bib25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2017.03.032","article-title":"Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia","volume":"261","author":"Arai","year":"2017","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.numecd.2023.02.011_bib26","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2337\/dc17-1589","article-title":"Effects of pemafibrate, a novel selective PPARalpha modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"41","author":"Araki","year":"2018","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.numecd.2023.02.011_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","article-title":"Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor alpha modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial","volume":"12","author":"Ishibashi","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.numecd.2023.02.011_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030706","article-title":"Of the KSGOB: long-term efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMalpha), in dyslipidemic patients with renal impairment","volume":"20","author":"Yokote","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.numecd.2023.02.011_bib29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12933-021-01291-w","article-title":"Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials","volume":"20","author":"Yokote","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.numecd.2023.02.011_bib30","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"9943","key":"10.1016\/j.numecd.2023.02.011_bib31","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.numecd.2023.02.011_bib32","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.atherosclerosis.2014.08.028","article-title":"Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS)","volume":"237","author":"Iso","year":"2014","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.numecd.2023.02.011_bib33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.numecd.2023.02.011_bib34","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI112713","article-title":"Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in\u00a0vivo","volume":"78","author":"Ginsberg","year":"1986","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.numecd.2023.02.011_bib35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/0021-9150(76)90016-2","article-title":"Changing relative proportions of apolipoproteins CII and CIII of very low density lipoproteins in hypertriglyceridaemia","volume":"23","author":"Carlson","year":"1976","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.numecd.2023.02.011_bib36","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jacl.2018.06.010","article-title":"Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia","volume":"12","author":"Yamashita","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.numecd.2023.02.011_bib37","first-page":"343","article-title":"Low-density lipoprotein cholesterol\/apolipoprotein B ratio may be a useful index that differs in statin-treated patients\u00a0with\u00a0and without coronary artery disease: a case control study","volume":"52","author":"Tani","year":"2011","journal-title":"Int\u00a0Heart J"},{"issue":"2","key":"10.1016\/j.numecd.2023.02.011_bib38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5551\/jat.12.67","article-title":"Measurement of small dense low-density lipoprotein particles","volume":"12","author":"Hirano","year":"2005","journal-title":"J Atherosclerosis Thromb"},{"issue":"1","key":"10.1016\/j.numecd.2023.02.011_bib39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jjcc.2013.06.018","article-title":"Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size","volume":"63","author":"Tani","year":"2014","journal-title":"J Cardiol"},{"issue":"5","key":"10.1016\/j.numecd.2023.02.011_bib40","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5551\/jat.48918","article-title":"Clinical applications of a novel selective PPARalpha modulator, pemafibrate, in dyslipidemia and metabolic diseases","volume":"26","author":"Yamashita","year":"2019","journal-title":"J Atherosclerosis Thromb"},{"issue":"22","key":"10.1016\/j.numecd.2023.02.011_bib41","article-title":"Efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha): pooled analysis of phase 2 and 3 studies in\u00a0dyslipidemic\u00a0patients with or without statin combination","volume":"20","author":"Yamashita","year":"2019","journal-title":"Int\u00a0J\u00a0Mol Sci"},{"issue":"10","key":"10.1016\/j.numecd.2023.02.011_bib42","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475323000698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475323000698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:24:46Z","timestamp":1760545486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475323000698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0939475323000698"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2023.02.011","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2023.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}]}}